Probiotics and Synbiotics Patents: Who Leads, Where Gaps Are 2026
- 195 of 505 records sit with the top five assignees alone — 38.6% of everything in scope, with a long tail of single-digit filers behind them.
- Filing peaked in 2020 at 57 and 2021-2024 shows a -40% move from 25 to 15; 2025-2026 figures are still filling in as publication catches up with filing.
- A23K animal feed sits at 20.4% of records — a sizeable adjacent claim zone that sits outside the human-nutrition core most filers are chasing.
Filing growth compares 2021 (25 records) with 2024 (15) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 505 records in scope (CR5), not by the ranked leaders only.
What the probiotics and synbiotics patent record actually shows
The dataset covers 505 published records filed or published between 2015 and mid-2026, searched against language tying probiotic or synbiotic formulation to strain viability, microencapsulation, gastric survival and shelf-life stability claims. This is a formulation-and-delivery corpus more than a strain-discovery one: the search terms center on keeping organisms alive and effective through manufacturing, storage and the gut, not on isolating novel microbial species.
Filing concentrates hard at the top of the assignee ranking, but the field is far from a duopoly: beyond the leading names the ranking thins into single- and double-digit filers, and most of the 100 ranked companies hold only a handful of families each. Technology composition confirms the formulation-first read — medicinal preparations and microorganism/genetic engineering classes dominate, food and animal feed classes trail but are far from negligible.
Filing trend and technology composition
Two views of the same 505-record set: how filing volume has moved year over year, and which IPC subclasses carry the claims.
Filing trend, 2017-2026
Filings rose from 42 in 2017 to a peak of 57 in 2020, then eased to 25 by 2021. The 2021-2024 window shows a -40% move, from 25 down to 15 — the last span long enough to read as complete. 2025 and 2026 counts are still low because publication typically lags filing by around 18 months; treat the tail end of the chart as incomplete, not as a slowdown.
IPC subclass composition
A61K (medicinal preparations) touches 77.8% of the 505 records, with C12N (microorganisms and genetic engineering) at 43.0% and A23L (foods and non-alcoholic beverages) at 40.8% close behind. A61P (therapeutic activity), A23K (animal feed) and the smaller A01N, A23P and C12Q subclasses round out the picture — each record can carry several classes, so these shares add to well over 100%, which is expected and reflects formulations claimed across pharmaceutical, food and feed contexts at once.
Shares are the percentage of the 505 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Probiotics and Synbiotics in Nutrition with Eureka
This page is one run against one query. Ask Eureka your own question about probiotics and synbiotics in nutrition and every answer comes back with the patent numbers behind it.
Try EurekaThe most-cited records in this corpus
US20230114656A1 — Products and methods for extending the shelf life of water sensitive products
Filed by Bonafide Health, LLC and published 2023-04-13, this record claims lactoferrin-based compositions that let formulators combine ingredients previously incompatible or unstable together — including probiotic actives — without resorting to capsule-in-capsule construction. The approach targets a specific stability failure mode: moisture and stability conflicts between an active ingredient (probiotic, supplement or foodstuff) and the rest of the formulation matrix.Abstract trimmed for length; see the full record for complete claim language.
View full record| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | WO2014152338A1 | Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents | 217 |
| 2 | US20050266069A1 | Stable probiotic microsphere compositions and their methods of preparation | 159 |
| 3 | WO2010138522A2 | Stable dry powder composition comprising biologically active microorganisms and/or bioactive materials and me… | 130 |
| 4 | US20110189132A1 | Microbial product containing multiple microorganisms | 113 |
| 5 | WO2011094469A2 | Dry glassy composition comprising a bioactive material | 89 |
| 6 | US20030165472A1 | Storage and delivery of micro-organisms | 82 |
| 7 | US20120135017A1 | Stable dry powder composition comprising biologically active microorganisms and/or bioactive materials and me… | 67 |
| 8 | US20120039956A1 | Dry storage stabilizing composition for biological materials | 66 |
| 9 | US20160022592A1 | Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents | 62 |
| 10 | US7939061B2 | Cell and enzyme compositions for modulating bile acids, cholesterol and triglycerides | 60 |
Citation counts inside a searched corpus skew toward older filings that have had longer to accumulate citations — read them as a signal of influence on later filers, not as a ranking of current importance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers mean for a filing decision
Three read-throughs from the concentration, trend and jurisdiction data.
The top of the field is crowded, most of it is not
The five leading assignees hold 195 of the 505 records in scope, and the top ten hold 271 — over half the corpus. Below that line, the ranking of 100 companies thins quickly into single-digit filers, which means most of the technical space is claimed by entities with only one or two families rather than by a small cartel of repeat filers.
Read the recent years with the publication lag in mind
Filing peaked at 57 in 2020, then the 2021-2024 span moved from 25 down to 15, a -40% change. That is the last window long enough to call complete; 2025 and 2026 totals will keep rising as publication lag closes the gap, so treat the most recent bars in any chart as a floor, not a ceiling.
US and European filings anchor the corpus
The United States leads receiving offices with 123 filings, ahead of the EPO at 72 and WIPO/PCT at 58; Australia, Canada and India each carry 34-39. That spread suggests applicants are pursuing US and European protection first and using PCT and secondary markets selectively rather than filing everywhere by default.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to probiotics and synbiotics in nutrition, with the prior art for and against each one.
Who is filing, and where the gaps sit
The assignee ranking covers 100 companies counted in records — the full set the data endpoint returns, not a top-50 or top-100 cut. A leader at 103 records sits well ahead of fifth place at 20 and tenth place at 14, then the tail lengthens fast.
One filer stands apart from the rest of the ranking
The top-ranked assignee holds 103 records, more than five times fifth place at 20. That gap is unusually wide for this kind of corpus and signals a company that has treated formulation and delivery claims as core IP rather than incidental filings.
The next tier is tightly bunched
Between fifth place (20 records) and tenth place (14 records) the gap is narrow, suggesting an active group of mid-sized filers rather than a sharp cliff. This is where a freedom-to-operate review needs the most care, since none of these players dominates any single sub-claim.
Joint filings are the exception, not the norm
Only 10 co-assignee pairs appear across the corpus, and the strongest of these still represents a small fraction of either party's total output. Most protection here is built by single entities filing alone, not through joint ventures or shared R&D filings.
| Assignee | Recent year | YoY |
|---|---|---|
| Advanced BioNutrition Corp | 0 | — |
| 9286 3620 Quebec Inc | 0 | — |
| TheraBiome LLC | 0 | — |
| MICROBIOS INC | 0 | — |
| Biotics | 0 | — |
| Research Institute at Nationwide Children's Hospital | 0 | — |
| President and Fellows of Harvard College | 0 | — |
| Synergia Life Sciences Pvt Ltd | 0 | — |
Where to take this analysis
The dataset points to specific next steps depending on whether the goal is freedom-to-operate, licensing, or identifying open claim space.
Map claims against the top-ten filers directly
With 53.7% of records held by ten assignees, a claim-by-claim comparison against just those ten covers most of the field's dense prior art in one pass.
Run a claim comparison in EurekaTest draft claims against the under-claimed branches
Feed-grade encapsulation, assay methods and shaped-food carriers show lower filing density than the A61K/C12N core — worth checking before assuming the space is occupied.
Explore white space in EurekaCommon questions about probiotic and synbiotic patents
This dataset counts 505 published records between 2015 and mid-2026, with filing activity peaking at 57 in 2020. The 2021-2024 span, the last window long enough to read as complete, moved from 25 down to 15 filings, a -40% change. Figures for 2025 and 2026 are still incomplete because publication typically lags actual filing by around 18 months, so the most recent bars in any trend chart will keep rising as more records surface.
The assignee ranking covers 100 companies, with a single leader holding 103 records — well ahead of fifth place at 20 and tenth place at 14. The top five combined hold 195 records, 38.6% of the 505 in scope, and the top ten hold 271, or 53.7%. Below that tier the ranking thins quickly into companies with only a handful of families each, so the field is concentrated at the top but has a genuinely long tail beneath it.
Medicinal preparations (IPC class A61K) appear in 77.8% of the 505 records, followed by microorganisms and genetic engineering (C12N) at 43.0% and foods and non-alcoholic beverages (A23L) at 40.8%. Animal feed (A23K) sits at 20.4%, meaningfully lower than the human-nutrition-facing classes. Because a single record can carry multiple IPC classes, these percentages add up to more than 100%, which reflects formulations claimed across pharmaceutical, food and feed uses simultaneously rather than any data error.
Sub-areas adjacent to the dense A61K/C12N/A23L core show noticeably lower filing density in this corpus, including feed-grade encapsulation methods, enzyme and DNA-based viability assay techniques under C12Q, and shaped or formed food carriers for live strains under A23P. These are not unclaimed, but they carry far fewer records than the medicinal-preparation core, making them worth a targeted prior-art check before assuming the space is occupied. Co-assignee filing is also rare across the corpus, with only 10 joint-filing pairs identified, suggesting collaborative filing itself is an underused route.
The United States leads as a receiving office with 123 filings in this dataset, ahead of the European Patent Office at 72 and the WIPO/PCT route at 58. Australia (39), Canada (35) and India (34) follow at a noticeably lower but still active level. This pattern suggests applicants prioritize US and European protection directly, then use PCT filing and select secondary markets rather than filing broadly across every jurisdiction by default.
Research Probiotics and Synbiotics in Nutrition in depth with Eureka
Go past this page: query the whole probiotics and synbiotics in nutrition corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.